The estimated Net Worth of Yafei Wen is at least $191 Тысяча dollars as of 16 May 2023. Ms Wen owns over 43,452 units of Invitae Corp stock worth over $14,006 and over the last 3 years she sold NVTA stock worth over $177,104.
Ms has made over 4 trades of the Invitae Corp stock since 2022, according to the Form 4 filled with the SEC. Most recently she sold 43,452 units of NVTA stock worth $86,469 on 16 May 2023.
The largest trade she's ever made was selling 43,452 units of Invitae Corp stock on 16 May 2023 worth over $86,469. On average, Ms trades about 8,301 units every 54 days since 2021. As of 16 May 2023 she still owns at least 700,297 units of Invitae Corp stock.
You can see the complete history of Ms Wen stock trades at the bottom of the page.
Yafei Wen is the Chief Financial Officer at Invitae Corp.
Ms Wen is 49, she's been the Chief Financial Officer of Invitae Corp since . There are 10 older and 7 younger executives at Invitae Corp. The oldest executive at Invitae Corp is Dr. Robert L. Nussbaum, 71, who is the Chief Medical Officer.
Yafei's mailing address filed with the SEC is C/O INVITAE CORPORATION, 1400 16TH STREET, SAN FRANCISCO, CA, 94103.
Over the last 10 years, insiders at Invitae Corp have traded over $68,349,838 worth of Invitae Corp stock and bought 2,982,686 units worth $18,086,236 . The most active insiders traders include Bros. Advisors Lp Baker Bro..., Bros. Advisors Lpbaker Feli... и James E Deerfield Mgmt L.P..... On average, Invitae Corp executives and independent directors trade stock every 14 days with the average trade being worth of $540. The most recent stock trade was executed by Robert L Nussbaum on 13 June 2023, trading 7,086 units of NVTA stock currently worth $9,779.
invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people. specializing in genetic diagnostics for hereditary disorders, invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today. choose from our curated panels or design your own test for the same low price. today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. together we can improve healthcare for billions of people.
Invitae Corp executives and other stock owners filed with the SEC include: